Interval prolongation of etanercept in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a randomized controlled trial
Authors' conclusion
Etanercept tapering can be done without losing efficacy in RA, PsA, and AS patients in sustained MDA.
Study context
- Population
- Patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), or ankylosing spondylitis (AS) with sustained minimal disease activity (MDA) on etanercept
- Participants
- 160 patients
- Comparison
- Doubling the etanercept dosing interval at baseline, then discontinuation at 6 months, vs continuation of the standard dose
- Primary endpoint
- Proportion of patients maintaining MDA
- Follow-up
- 6 months
Methodological detailsopen-label, 18-month
- Open-label
- 18-month
Primary result
As reported in the abstract
MDA maintained
P = 0.15
Further findings
Median etanercept concentrations (decrease)
- Decreased from 1.50 µg/mL (IQR 1.06- 2.65) to 0.46 µg/mL (0.28-0.92)
Successful etanercept discontinuation with maintained MDA for at least 6 months
- Discontinued successfully, in total
- 40%
Original publication
Interval prolongation of etanercept in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a randomized controlled trial. Scand J Rheumatol. Published 2 March 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →